Genetic variability of vascular endothelial growth factor and prognosis of head and neck cancer in a Brazilian population

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 2, 2010, Pages 127-133

  Ruiz, M T ^a   Biselli, P M ^a   Maniglia, J V ^a   Pavarino Bertelli, E C ^a   Goloni Bertollo, E M ^a  

^a FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

Genetic; Head and neck cancer; Polymorphism; VEGF gene

Indexed keywords

GENOMIC DNA; VASCULOTROPIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DEMOGRAPHY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

EID: 76649105400     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009007500036     Document Type: Article

References (38)

1. Walker DM, Boey G, McDonald LA. The pathology of oral cancer. Pathology 2003; 35: 376-383.
2. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006; 59: 445-453.
3. Instituto Nacional do Câncer. http://www.inca.gov.br.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
5. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-1225.
6. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
7. Maeda T, Matsumura S, Hiranuma H, Jikko A, Furukawa S, Ishida T, et al. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J Clin Pathol 1998; 51: 771-775.
8. Lim SC. Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma. Biomed Pharmacother 2005; 59 (Suppl 2): S366-S369.
9. Mohammadi M, Ollier WE, Hutchinson IV. A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells. Hum Immunol 2003; 64: S125.
10. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260-264.
11. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-1639.
12. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 2002; 3: 229-232.
13. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005; 65: 70-75.
14. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004; 46: 293-298.
15. Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 571-575.
16. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-3372.
17. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006; 35: 21-28.
18. Kim JG, Sohn SK, Chae YS, Cho YY, Bae HI, Yan G, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007; 18: 1030-1036.
19. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65: 5015-5019.
20. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005; 11: 3647-3653.
21. Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH, Tsai FJ. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 2005; 41: 497-502.
22. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, et al. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 2007; 133: 787-791.
23. Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, et al. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 2009; 45: 247-253.
24. Cheng CY, Chang CS, Liu CJ, Kao SY. Vascular endothelial growth factor 936 C/T polymorphism is associated with vascular invasion in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 79-84.
25. Nasr HB, Chahed K, Bouaouina N, Chouchane L. Functional vascular endothelial growth factor -2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression. Clin Chim Acta 2008; 395: 124-129.
26. Unal ZN, Unal M, Bagdatoglu OT, Polat G, Atik U. Genetic polymorphism of VEGF-1154 (A/G) in laryngeal squamous cell carcinoma. Arch Med Res 2008; 39: 209-211.
27. Sobin LH, Wittelind CH. International union against cancer: TNM classification of malignant tumours. 6th edn. New York: Wiley; 2002.
28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
29. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371: 1695-1709.
30. Goldstein DP, Irish JC. Head and neck squamous cell carcinoma in the young patient. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 207-211.
31. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-1249.
32. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997; 33: 369-374.
33. Wong YK, Liu CJ, Kwan PC, Chao SY. Microvascular density and vascular endothelial growth factor immunoreactivity as predictors of regional lymph node metastasis from betel-associated oral squamous cell carcinoma. J Oral Maxillofac Surg 2003; 61: 1257-1262.
34. Shang ZJ, Li JR. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression. J Oral Pathol Med 2005; 34: 134-139.
35. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62: 4123-4131.
36. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005; 23: 1782-1790.
37. Ferroni P, Spila A, Martini F, D'Alessandro R, Mariotti S, Del Monte G, et al. Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Oncology 2005; 69: 145-153.
38. Uehara M, Sano K, Ikeda H, Sekine J, Irie A, Yokota T, et al. Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma. Oral Oncol 2004; 40: 321-325.